In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. GSK is doling out $1 billion in cash for the Boston-based biotech, tacking on the potential for an additional $150 million regulatory approval milestone payment. Source: Fierce Biotech 13/1/25